Need for Prompt Epinephrine Use in Anaphylaxis
May 21, 2025

A panelist discusses how anaphylaxis should be defined and treated promptly with epinephrine, highlighting the concerning statistic that not all patients who experience anaphylaxis receive this critical first-line treatment.

Primary Care Clinicians Diagnose Nearly Half of Youth MDD, Report Reveals, Often During a Crisis
May 21, 2025

Youth depression is often diagnosed during crisis events, underscoring the need for primary care education and enhanced collaborative care resources.

FDA Narrows COVID-19 Vaccine Access to High-Risk Groups, Demands New Trials for Healthy Adults
May 21, 2025

The FDA's new approach to evaluating and approving COVID-19 vaccines will move the US away from a one-size-fits-all approach and closer to policy in other countries.

Elinzanetant Effective for VMS Across BMI, Smoking Status: Daily Dose
May 21, 2025

Your daily dose of the clinical news you may have missed.

PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD
May 20, 2025

ACOG 2025: Elizabeth Mollard, PhD, discusses her research on how Medicaid policies influence postpartum depression screening rates.

Single Dose of Arexvy RSV Vaccine Shows 3-Year Protection in Older Adults: Daily Dose
May 20, 2025

Your daily dose of the clinical news you may have missed.

Real-World Memory Clinic Data Suggest Lecanemab Use Is Feasible, Practical for Adults with Alzheimer Disease
May 20, 2025

Adults with early AD who were treated with lecanemab in a specialty memory clinic experienced adverse events comparable to those seen in clinical trials.

“I’m Just Tired”: Listening for the Words Patients Actually Use
May 20, 2025

ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.

Investigational Oral Medication for OSA Meets Primary Endpoints in Phase 3 Clinical Trial
May 20, 2025

The anti-apneic neuromuscular modulator AD109 targets the root cause of OSA by increasing upper airway muscle tone during sleep, according to Apnimed.

FDA Grants Novavax COVID-19 Vaccine Full Approval for High-Risk Groups
May 20, 2025

Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.